{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:21:51Z","timestamp":1754482911414,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Characterized by ventricular and vascular stiffness, heart failure with preserved ejection fraction (HFpEF) has led to high morbidity and mortality. As azilsartan is an angiotensin receptor blocker with the highest myocardial and vascular affinities, azilsartan may improve the left ventricular (LV) diastolic function in patients with hypertension and either HFpEF or HF with mildly reduced ejection fraction (HFmrEF) more than candesartan. In this randomized, open-label trial, we randomly assigned 193 hypertensive patients with HF and LV ejection fraction\u2009\u2265\u200945% to 20 mg of azilsartan (n\u2009=\u200995) or 8 mg of candesartan (n\u2009=\u200998), once daily for 48 weeks. After the initiation of treatment, changes in the doses of the study drugs were permitted based on the patient\u2019s conditions, including blood pressure (median dose at 48 weeks: azilsartan 20.0 mg\/day, candesartan 8.0 mg\/day). The primary endpoint was the baseline-adjusted change in the ratio of peak early diastolic transmitral flow velocity (E) to early diastolic mitral annular velocity (e\u2032) (E\/e\u2032). Adjusted least-squares mean (LSM) change in E\/e\u2032 was\u2009\u2212\u20090.8 (95% confidence interval [CI]\u2009\u2212\u20091.49 to\u2009\u2212\u20090.04) in the azilsartan group and 0.2 (95% CI\u2009\u2212\u20090.49 to 0.94) in the candesartan group, providing the LSM differences of\u2009\u2212\u20091.0 (95% CI\u2009\u2212\u20092.01 to 0.03, P\u2009=\u20090.057). The median change in left atrial volume index was \u2013 2.7 mL\/m<jats:sup>2<\/jats:sup> with azilsartan vs 1.4 mL\/m<jats:sup>2<\/jats:sup> with candesartan (P\u2009=\u20090.091). The frequency of adverse events related to hypotension and hyperkalemia did not differ between the groups. The current study did not provide strong evidence that azilsartan improves LV diastolic dysfunction, and further confirmatory study is required.<\/jats:p>","DOI":"10.1038\/s41598-023-39779-y","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:02:11Z","timestamp":1690970531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial"],"prefix":"10.1038","volume":"13","author":[{"given":"Shin","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takahama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Ajioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Arikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaharu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yorihiko","family":"Higashino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hiramitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Iwahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Kioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Jae","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Motoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Sasaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"39779_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251\u2013259 (2006).","journal-title":"N. Engl. J. Med."},{"key":"39779_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","volume":"64","author":"BR Lindman","year":"2014","unstructured":"Lindman, B. R. et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: A RELAX trial ancillary study. J. Am. Coll. Cardiol. 64, 541\u2013554 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"39779_CR3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"BA Borlaug","year":"2011","unstructured":"Borlaug, B. A. & Paulus, W. J. Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur. Heart J. 32, 670\u2013767 (2011).","journal-title":"Eur. Heart J."},{"key":"39779_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jacc.2007.07.032","volume":"50","author":"BA Borlaug","year":"2007","unstructured":"Borlaug, B. A. et al. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J. Am. Coll. Cardiol. 50, 1570\u20131577 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"39779_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1161\/01.CIR.0000048123.22359.A0","volume":"107","author":"M Kawaguchi","year":"2003","unstructured":"Kawaguchi, M., Hay, I., Fetics, B. & Kass, D. A. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 107, 714\u2013720 (2003).","journal-title":"Circulation"},{"key":"39779_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00788524","volume":"88","author":"VJ Dzau","year":"1993","unstructured":"Dzau, V. J. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res. Cardiol. 88, 1\u201314 (1993).","journal-title":"Basic Res. Cardiol."},{"key":"39779_CR7","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie, B. M. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456\u20132467 (2008).","journal-title":"N. Engl. J. Med."},{"key":"39779_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","volume":"4","author":"IS Anand","year":"2011","unstructured":"Anand, I. S. et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: Findings from the I-PRESERVE trial. Circ. Heart Fail. 4, 569\u2013577 (2011).","journal-title":"Circ. Heart Fail."},{"key":"39779_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger, C. B. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 362, 772\u2013776 (2003).","journal-title":"Lancet"},{"key":"39779_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray, J. J. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362, 767\u2013771 (2003).","journal-title":"Lancet"},{"key":"39779_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf, S. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet 362, 777\u2013781 (2003).","journal-title":"Lancet"},{"key":"39779_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/jpet.110.176636","volume":"336","author":"M Ojima","year":"2011","unstructured":"Ojima, M. et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, Azilsartan, in receptor binding and function studies. J. Pharmacol. Exp. Ther. 336, 801\u2013808 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"39779_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1254\/jphs.13167FP","volume":"123","author":"S Takai","year":"2013","unstructured":"Takai, S., Jin, D., Sakonjo, H., Takubo, T. & Nakanishi, T. Significance of the vascular concentration of angiotensin II-receptor blockers on the mechanism of lowering blood pressure in spontaneously hypertensive rats. J. Pharmacol. Sci. 123, 371\u2013379 (2013).","journal-title":"J. Pharmacol. Sci."},{"key":"39779_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijge.2015.06.003","volume":"9","author":"M Sakamoto","year":"2015","unstructured":"Sakamoto, M. et al. Azilsartan, but not candesartan improves left ventricular diastolic function in patients with hypertension and heart failure. Int. J. Gerontol. 9, 201\u2013205 (2015).","journal-title":"Int. J. Gerontol."},{"key":"39779_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 24, 4\u2013131 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"39779_CR16","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e876\u2013e894 (2022).","journal-title":"Circulation"},{"key":"39779_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","volume":"289","author":"MM Redfield","year":"2003","unstructured":"Redfield, M. M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 289, 194\u2013202 (2003).","journal-title":"JAMA"},{"key":"39779_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1253\/circj.CJ-08-0457","volume":"73","author":"H Okura","year":"2009","unstructured":"Okura, H. et al. Elevated E\/E\u2019 predicts prognosis in congestive heart failure patients with preserved systolic function. Circ. J. 73, 86\u201391 (2009).","journal-title":"Circ. J."},{"key":"39779_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda, M. et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: The EDIFY randomized placebo-controlled trial. Eur. J. Heart Fail. 19, 1495\u20131503 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"39779_CR20","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/ejhf.1743","volume":"22","author":"V Carubelli","year":"2020","unstructured":"Carubelli, V. et al. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: A randomised, placebo-controlled trial. Eur. J. Heart Fail. 22, 1684\u20131693 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"39779_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1253\/circj.CJ-16-0106","volume":"80","author":"T Hayashi","year":"2016","unstructured":"Hayashi, T. et al. Left ventricular global strain for estimating relaxation and filling pressure\u2014A multicenter study. Circ. J. 80, 1163\u20131170 (2016).","journal-title":"Circ. J."},{"key":"39779_CR22","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/CIRCULATIONAHA.106.662882","volume":"115","author":"J Wang","year":"2007","unstructured":"Wang, J., Khoury, D. S., Thohan, V., Torre-Amione, G. & Nagueh, S. F. Global diastolic strain rate for the assessment of left ventricular relaxation and filling pressures. Circulation 115, 1376\u20131383 (2007).","journal-title":"Circulation"},{"key":"39779_CR23","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1253\/circj.CJ-12-0264","volume":"76","author":"K Takigiku","year":"2012","unstructured":"Takigiku, K. et al. Normal range of left ventricular 2-dimensional strain: Japanese ultrasound speckle tracking of the left ventricle (JUSTICE) study. Circ. J. 76, 2623\u20132632 (2012).","journal-title":"Circ. J."},{"key":"39779_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/10641963.2017.1407332","volume":"40","author":"D Zhou","year":"2018","unstructured":"Zhou, D. et al. Prognostic value of tissue Doppler E\/e\u2019 ratio in hypertension patients with preserved left ventricular ejection fraction. Clin. Exp. Hypertens. 40, 554\u2013559 (2018).","journal-title":"Clin. Exp. Hypertens."},{"key":"39779_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2169\/internalmedicine.51.6250","volume":"51","author":"Y Iwabuchi","year":"2012","unstructured":"Iwabuchi, Y., Ogawa, T., Inoue, T., Otsuka, K. & Nitta, K. Elevated E\/E\u2019 predicts cardiovascular events in hemodialysis patients with preserved systolic function. Intern. Med. 51, 155\u2013160 (2012).","journal-title":"Intern. Med."},{"key":"39779_CR26","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","volume":"74","author":"AM Shah","year":"2019","unstructured":"Shah, A. M. et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J. Am. Coll. Cardiol. 74, 2858\u20132873 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"39779_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1136\/hrt.2005.082594","volume":"92","author":"H Okura","year":"2006","unstructured":"Okura, H. et al. Tissue Doppler-derived index of left ventricular filling pressure, E\/E\u2019, predicts survival of patients with non-valvular atrial fibrillation. Heart 92, 1248\u20131252 (2006).","journal-title":"Heart"},{"key":"39779_CR28","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.106.659763","volume":"115","author":"CS Lam","year":"2007","unstructured":"Lam, C. S. et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115, 1982\u20131990 (2007).","journal-title":"Circulation"},{"key":"39779_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/01.RES.32.2.178","volume":"32","author":"G Elzinga","year":"1973","unstructured":"Elzinga, G. & Westerhof, N. Pressure and flow generated by the left ventricle against different impedances. Circ. Res. 32, 178\u2013186 (1973).","journal-title":"Circ. Res."},{"key":"39779_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/01.RES.55.1.31","volume":"55","author":"M Hori","year":"1984","unstructured":"Hori, M. et al. Ejection timing as a major determinant of left ventricular relaxation rate in isolated perfused canine heart. Circ. Res. 55, 31\u201338 (1984).","journal-title":"Circ. Res."},{"key":"39779_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2014.20","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto, K. et al. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2014). Hypertens. Res. 37, 253\u2013390 (2014).","journal-title":"Hypertens. Res."},{"key":"39779_CR32","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(05)67760-4","volume":"366","author":"BB Granger","year":"2005","unstructured":"Granger, B. B. et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomised, controlled clinical trial. Lancet 366, 2005\u20132011 (2005).","journal-title":"Lancet"},{"key":"39779_CR33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1388-9842(03)00162-4","volume":"5","author":"A Matsumori","year":"2003","unstructured":"Matsumori, A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur. J. Heart Fail. 5, 669\u2013677 (2003).","journal-title":"Eur. J. Heart Fail."},{"key":"39779_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10557-018-6799-5","volume":"32","author":"H Takahama","year":"2018","unstructured":"Takahama, H. et al. Rationale and design of the multicenter trial on Japan working group on the effects of angiotensin receptor blockers selection (Azilsartan vs. Candesartan) on diastolic function in the patients suffering from heart failure with preserved ejection fraction: J-TASTE trial. Cardiovasc. Drugs Ther. 32, 381\u2013388 (2018).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"39779_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"LG Rudski","year":"2010","unstructured":"Rudski, L. G. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echocardiogr. 23, 685\u2013713 (2010).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"39779_CR36","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/S0735-1097(01)01651-5","volume":"38","author":"CH Chen","year":"2001","unstructured":"Chen, C. H. et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J. Am. Coll. Cardiol. 38, 2028\u20132034 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"39779_CR37","doi-asserted-by":"publisher","first-page":"H501","DOI":"10.1152\/ajpheart.00138.2005","volume":"289","author":"D Burkhoff","year":"2005","unstructured":"Burkhoff, D., Mirsky, I. & Suga, H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: A guide for clinical, translational, and basic researchers. Am. J. Physiol. Heart Circ. Physiol. 289, H501-512 (2005).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39779-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:10:27Z","timestamp":1690971027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39779-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39779"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39779-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YH, NI, YJL, K Matsuoka, S Matsuoka, HM, SN, T Sasaoka, S Takiuchi, and MY have nothing to disclose. SI reports a grant from Japan Society for the Promotion of Science, outside the submitted work. HT reports grants from the Japanese government, outside the submitted work. M Asakura reports personal fees from AstraZeneca, Ono, Otsuka, Novartis, Bayer, Daiichi Sankyo, Takeda, Pfizer, Boehringer Ingelheim, Mitsubishi Tanabe, Taisho, Kowa, Jansen, Nippon Shinyaku, and Astellas, outside the submitted work. YA reports grants from Japan Society for the Promotion of Science, grants from Japanese Agency for Medical Research and Development, grants from Japan Health Foundation, personal fees from AstraZeneca, personal fees from Novartis, personal fees from Daiichi Sankyo, personal fees from Otsuka, personal fees from Boehringer Ingelheim, personal fees from Ono, personal fees from Astellas, personal fees from Bayer, personal fees from Eli Lilly, and personal fees from Edwards Lifesciences, outside the submitted work. M Ajioka reports personal fees from Ono, Novartis, Mitsubishi Tanabe, Pfizer, Daiichi Sankyo, and Otsuka, outside the submitted work. T Anzai reports consulting fees from Terumo, consulting fees from Amgen K.K., personal fees from TOA EIYO, personal fees from Novartis, personal fees from Pharma K.K., personal fees from Bayer, personal fees from Pfizer, personal fees from Bristol-Myers Squibb, personal fees from Ono, personal fees from Otsuka, personal fees from Daiichi Sankyo, personal fees from Mitsubishi Tanabe, personal fees from Boehringer Ingelheim, and personal fees from Takeda, outside the submitted work. T Arikawa reports personal fees from Teijin, outside the submitted work. TH reports personal fees from Otsuka, Ono, AstraZeneca, Medtronic, Daiichi Sankyo, Boehringer Ingelheim, Kowa, Toyobo, Novartis, and TOA EIYO, outside the submitted work. SH reports personal fees from Takeda, Novartis, Otsuka, Bayer, Mitsubishi Tanabe, Daiichi Sankyo, MSD, Teijin, Kowa, Kyowa Kirin, Taisho, Boehringer Ingelheim, Shionogi, Ono, and Sumitomo Dainippon, outside the submitted work. CI reports personal fees from Daiichi Sankyo, Edwards Lifesciences, Bristol-Myers Squibb, Otsuka, Cannon Medical Systems, Sumitomo Dainippon, TOA EIYO, MSD, Pfizer, Boehringer Ingelheim, Teijin, Tsumura, and Novartis, outside the submitted work. K Kimura reports grants from the Research Institute for Production Development, grants from CSL Behring, grants from Mebix, grants from Takeda, grants from Bayer, grants from AstraZeneca, grants from Nippon Shinyaku, grants from Boehringer Ingelheim, grants from Astellas, grants from Abbott Vascular Japan, grants from Medtronic, grants from Kowa, contracts free from National Cerebral and Cardiovascular Center, contracts free from Juntendo, consulting fees from Idorsia Pharmaceuticals Japan, personal fees from Mitsubishi Tanabe, personal fees from Kowa, personal fees from Daiichi Sankyo, personal fees from Bayer, personal fees from AstraZeneca, personal fees from Mochida, personal fees from Astellas, personal fees from MSD, personal fees from Boston Scientific, personal fees from Japan Cardiovascular Research Foundation, personal fees from Sanofi, personal fees from Bristol-Myers Squibb, personal fees from Sumitomo Dainippon, personal fees from Abbott Vascular Japan, personal fees from TOA EIYO, personal fees from Amgen Astellas BioPharma, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from FUJIFILM Toyama Chemical, personal fees from Otsuka, and personal fees from Pfizer, outside the submitted work. K Kinugawa reports personal fees from Otsuka, Nipro, Ono, Abiomed, and AstraZeneca, outside the submitted work. HK reports grants from Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Actelion Pharmaceuticals, GSK, and Nakatani foundation, outside the submitted work. TN reports grants from Japan Society for the Promotion of Science, personal fees from Nippon Shinyaku, personal fees from TOA EIYO, and personal fees from Daiichi Sankyo, outside the submitted work. AN reports grants from Grants-in-Aid for Scientific Research, MEXT, Japan, grants from Japan Agency for Medical Research and Development, grants from Japan Heart Foundation, consulting fees from CureApp, personal fees from CureApp, personal fees from Otsuka, personal fees from Kowa, personal fees from Daiichi Sankyo, personal fees from Amgen, support for attending meetings from CureApp, and participation on a Data Safety Monitoring Board or Advisory Board of CureApp, outside the submitted work. S Toyoda reports personal fees from Sumitomo Dainippon, JCR Pharmaceuticals, AstraZeneca, Otsuka, Ono, Sanofi, Daiichi Sankyo, Takeda, Mitsubishi Tanabe, Novartis, Novo Nordisk, Bayer, Pfizer, Bristol-Myers Squibb, and TOA EIYO, outside the submitted work. TU reports personal fees from Ono, Novartis, and Otsuka, outside the submitted work. TW reports personal fees from AstraZeneca, Ono, Novartis, Mitsubishi Tanabe, Takeda, Pfizer, Daiichi Sankyo, Otsuka, and Kowa, outside the submitted work. AY reports personal fees from Ono, Nippon Shinyaku, Novartis, Otsuka, Kowa, Pfizer, Bristol-Myers Squibb, TOA EIYO, AstraZeneca, Amgen, Boehringer Ingelheim, Takeda, Daiichi Sankyo, Bayer, and Mitsubishi Tanabe, outside the submitted work. T Sozu reports grants from Japan Society for the Promotion of Science, reports grants from Japan Agency for Medical Research and Development, consulting fees from Edwards Lifesciences, consulting fees from Ajinomoto Co, consulting fees from Nippon Kayaku, participation on a Data Safety Monitoring Board or Advisory Board of Otsuka, participation on a Data Safety Monitoring Board or Advisory Board of EPS International Holdings, and participation on a Data Safety Monitoring Board or Advisory Board of EPS Associates, outside the submitted work. MK reports grants from the Japanese government, during the conduct of the study; grants from the Japanese government, grants from Japan Heart Foundation, grants from Japan Cardiovascular Research Foundation, grants and personal fees from Takeda, personal fees from Daiichi Sankyo, grants and personal fees from Pfizer, grants and personal fees from Ono, grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, grants from Novartis, grants and personal fees from Mitsubishi Tanabe, personal fees from Kowa, personal fees from Otsuka, grants from Sanofi, personal fees from Amgen, personal fees from Toyama-Kagaku, grants and personal fees from Kureha, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12517"}}